Do analysts rate IMCC or GOVX?

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 14,975.38%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than IM Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation & earnings, IMCC or GOVX?

IM Cannabis has higher revenue and earnings than GeoVax Labs. IM Cannabis is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IM Cannabis $39.17M 0.02 -$8.10M -$1.75 N/A GeoVax Labs $852.28K 4.05 -$21.47M -$19.12 N/A

Is IMCC or GOVX more profitable?

GeoVax Labs has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. IM Cannabis' return on equity of -585.96% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets IM Cannabis -27.65% -585.96% -39.96% GeoVax Labs N/A -709.52% -399.33%

Do analysts rate DCOY or IMCC?

Decoy Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 509.76%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Decoy Therapeutics is more favorable than IM Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer IMCC or VCNX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, IMCC or VCNX?

IM Cannabis has higher revenue and earnings than Vaccinex. IM Cannabis is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IM Cannabis $39.17M 0.02 -$8.10M -$1.75 N/A Vaccinex $388K 7.91 -$20.25M -$48.27 N/A

Is IMCC or VCNX more profitable?

Vaccinex has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. Vaccinex's return on equity of 0.00% beat IM Cannabis' return on equity. Company Net Margins Return on Equity Return on Assets IM Cannabis -27.65% -585.96% -39.96% Vaccinex N/A N/A -383.58%

Which has higher valuation and earnings, VRAX or IMCC?

Virax Biolabs Group has higher earnings, but lower revenue than IM Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 310.40 -$5.02M N/A N/A IM Cannabis $39.17M 0.02 -$8.10M -$1.75 N/A

Do analysts prefer SNYR or IMCC?

Synergy CHC currently has a consensus price target of $6.25, indicating a potential upside of 3,307.85%. Given Synergy CHC's stronger consensus rating and higher possible upside, equities research analysts plainly believe Synergy CHC is more favorable than IM Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, SNYR or IMCC?

IM Cannabis has higher revenue and earnings than Synergy CHC. Synergy CHC is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synergy CHC $30.38M 0.09 -$12.34M -$1.40 N/A IM Cannabis $39.17M 0.02 -$8.10M -$1.75 N/A

Is SNYR or IMCC more profitable?

IM Cannabis has a net margin of -27.65% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of 0.00% beat IM Cannabis' return on equity. Company Net Margins Return on Equity Return on Assets Synergy CHC -60.02% N/A -30.30% IM Cannabis -27.65% -585.96% -39.96%

IM Cannabis (IMCC) Competitors

$0.14 +0.00 (+3.01%)

Closing price 07/21/2026 04:00 PM Eastern

Extended Trading

$0.14 0.00 (-0.66%)

As of 07/21/2026 07:58 PM Eastern

Compare

IMCC vs. GOVX, DCOY, VCNX, VRAX, and SNYR

Should you buy IM Cannabis stock or one of its competitors? MarketBeat compares IM Cannabis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IM Cannabis include GeoVax Labs (GOVX), Decoy Therapeutics (DCOY), Vaccinex (VCNX), Virax Biolabs Group (VRAX), and Synergy CHC (SNYR). These companies are all part of the "pharmaceutical products" industry.

How does IM Cannabis compare to GeoVax Labs?

IM Cannabis (NASDAQ:IMCC) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, GeoVax Labs had 2 more articles in the media than IM Cannabis. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 0.00 equaled GeoVax Labs'average media sentiment score.

Company	Overall Sentiment
IM Cannabis	Neutral
GeoVax Labs	Neutral

GeoVax Labs has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. IM Cannabis' return on equity of -585.96% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-27.65%	-585.96%	-39.96%
GeoVax Labs	N/A	-709.52%	-399.33%

IM Cannabis has higher revenue and earnings than GeoVax Labs. IM Cannabis is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.02	-$8.10M	-$1.75	N/A
GeoVax Labs	$852.28K	4.05	-$21.47M	-$19.12	N/A

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 14,975.38%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than IM Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

IM Cannabis has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.68, indicating that its stock price is 268% more volatile than the broader market.

Summary

GeoVax Labs beats IM Cannabis on 8 of the 14 factors compared between the two stocks.

How does IM Cannabis compare to Decoy Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and IM Cannabis (NASDAQ:IMCC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, Decoy Therapeutics had 1 more articles in the media than IM Cannabis. MarketBeat recorded 1 mentions for Decoy Therapeutics and 0 mentions for IM Cannabis. Decoy Therapeutics' average media sentiment score of 0.00 equaled IM Cannabis'average media sentiment score.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
IM Cannabis	Neutral

Decoy Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 509.76%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Decoy Therapeutics is more favorable than IM Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Decoy Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. Decoy Therapeutics' return on equity of -395.42% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
IM Cannabis	-27.65%	-585.96%	-39.96%

11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 1.7% of Decoy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Decoy Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market.

IM Cannabis has higher revenue and earnings than Decoy Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
IM Cannabis	$39.17M	0.02	-$8.10M	-$1.75	N/A

Summary

Decoy Therapeutics beats IM Cannabis on 9 of the 14 factors compared between the two stocks.

How does IM Cannabis compare to Vaccinex?

IM Cannabis (NASDAQ:IMCC) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

IM Cannabis has higher revenue and earnings than Vaccinex. IM Cannabis is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17M	0.02	-$8.10M	-$1.75	N/A
Vaccinex	$388K	7.91	-$20.25M	-$48.27	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

IM Cannabis has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

In the previous week, IM Cannabis' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
IM Cannabis	Neutral
Vaccinex	Neutral

Vaccinex has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. Vaccinex's return on equity of 0.00% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-27.65%	-585.96%	-39.96%
Vaccinex	N/A	N/A	-383.58%

Summary

IM Cannabis and Vaccinex tied by winning 6 of the 12 factors compared between the two stocks.

How does IM Cannabis compare to Virax Biolabs Group?

Virax Biolabs Group (NASDAQ:VRAX) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, Virax Biolabs Group had 4 more articles in the media than IM Cannabis. MarketBeat recorded 4 mentions for Virax Biolabs Group and 0 mentions for IM Cannabis. Virax Biolabs Group's average media sentiment score of 0.41 beat IM Cannabis' score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
IM Cannabis	Neutral

Virax Biolabs Group has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. Virax Biolabs Group's return on equity of 0.00% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
IM Cannabis	-27.65%	-585.96%	-39.96%

Virax Biolabs Group currently has a consensus target price of $25.00, indicating a potential upside of 544.33%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Virax Biolabs Group is more favorable than IM Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Virax Biolabs Group has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market.

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Virax Biolabs Group has higher earnings, but lower revenue than IM Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	310.40	-$5.02M	N/A	N/A
IM Cannabis	$39.17M	0.02	-$8.10M	-$1.75	N/A

Summary

Virax Biolabs Group beats IM Cannabis on 12 of the 14 factors compared between the two stocks.

How does IM Cannabis compare to Synergy CHC?

Synergy CHC (NASDAQ:SNYR) and IM Cannabis (NASDAQ:IMCC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Synergy CHC has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

IM Cannabis has higher revenue and earnings than Synergy CHC. Synergy CHC is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$30.38M	0.09	-$12.34M	-$1.40	N/A
IM Cannabis	$39.17M	0.02	-$8.10M	-$1.75	N/A

7.7% of IM Cannabis shares are held by institutional investors. 32.9% of Synergy CHC shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Synergy CHC had 2 more articles in the media than IM Cannabis. MarketBeat recorded 2 mentions for Synergy CHC and 0 mentions for IM Cannabis. Synergy CHC's average media sentiment score of 0.00 equaled IM Cannabis'average media sentiment score.

Company	Overall Sentiment
Synergy CHC	Neutral
IM Cannabis	Neutral

Synergy CHC currently has a consensus price target of $6.25, indicating a potential upside of 3,307.85%. Given Synergy CHC's stronger consensus rating and higher possible upside, equities research analysts plainly believe Synergy CHC is more favorable than IM Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IM Cannabis has a net margin of -27.65% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of 0.00% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	-60.02%	N/A	-30.30%
IM Cannabis	-27.65%	-585.96%	-39.96%

Summary

Synergy CHC beats IM Cannabis on 9 of the 15 factors compared between the two stocks.

Get IM Cannabis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMCC vs. The Competition

Export

Metric	IM Cannabis	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$830K	$8.72B	$6.80B	$12.32B
Dividend Yield	N/A	2.48%	2.67%	9.67%
P/E Ratio	-0.08	15.40	26.92	24.18
Price / Sales	0.02	7.28	483.73	80.05
Price / Cash	N/A	18.24	49.71	59.37
Price / Book	-0.28	3.25	10.67	6.25
Net Income	-$8.10M	$230.22M	$3.60B	$331.66M
7 Day Performance	-7.50%	-1.41%	-1.00%	-1.32%
1 Month Performance	-22.30%	-0.15%	1.58%	-1.74%
1 Year Performance	-95.56%	-2.37%	24.12%	18.04%

IM Cannabis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMCC IM Cannabis	0.0715 of 5 stars	$0.14 +3.0%	N/A	-95.5%	$830K	$39.17M	N/A	340
GOVX GeoVax Labs	2.1083 of 5 stars	$0.94 -6.9%	$150.00 +15,857.4%	-95.1%	$3.27M	$852.28K	N/A	10	News Coverage Positive News Upcoming Earnings
DCOY Decoy Therapeutics	1.4493 of 5 stars	$6.05 +5.2%	$30.00 +395.9%	N/A	$3.22M	N/A	N/A	20
VCNX Vaccinex	N/A	$1.16 flat	N/A	+15.9%	$3.02M	$388K	N/A	40	Gap Down
VRAX Virax Biolabs Group	2.7408 of 5 stars	$3.79 +9.7%	$25.00 +560.5%	-86.0%	$3.01M	$10K	N/A	5	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMCC) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IM Cannabis (IMCC) Competitors

IMCC vs. GOVX, DCOY, VCNX, VRAX, and SNYR

How does IM Cannabis compare to GeoVax Labs?

Summary

How does IM Cannabis compare to Decoy Therapeutics?

Summary

How does IM Cannabis compare to Vaccinex?

Summary

How does IM Cannabis compare to Virax Biolabs Group?

Summary

How does IM Cannabis compare to Synergy CHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC vs. The Competition

IM Cannabis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IM Cannabis (IMCC) Competitors

IMCC vs. GOVX, DCOY, VCNX, VRAX, and SNYR

How does IM Cannabis compare to GeoVax Labs?

Does the media refer more to IMCC or GOVX?

Is IMCC or GOVX more profitable?

Which has stronger valuation & earnings, IMCC or GOVX?

Do analysts rate IMCC or GOVX?

Do institutionals and insiders have more ownership in IMCC or GOVX?

Which has more volatility and risk, IMCC or GOVX?

Summary

How does IM Cannabis compare to Decoy Therapeutics?

Does the media prefer DCOY or IMCC?

Do analysts rate DCOY or IMCC?

Is DCOY or IMCC more profitable?

Do institutionals & insiders believe in DCOY or IMCC?

Which has more risk & volatility, DCOY or IMCC?

Which has stronger valuation & earnings, DCOY or IMCC?

Summary

How does IM Cannabis compare to Vaccinex?

Do institutionals and insiders have more ownership in IMCC or VCNX?

Which has higher valuation & earnings, IMCC or VCNX?

Do analysts prefer IMCC or VCNX?

Which has more risk & volatility, IMCC or VCNX?

Does the media favor IMCC or VCNX?

Is IMCC or VCNX more profitable?

Summary

How does IM Cannabis compare to Virax Biolabs Group?

Does the media favor VRAX or IMCC?

Is VRAX or IMCC more profitable?

Do analysts rate VRAX or IMCC?

Which has more volatility and risk, VRAX or IMCC?

Do insiders and institutionals believe in VRAX or IMCC?

Which has higher valuation and earnings, VRAX or IMCC?

Summary

How does IM Cannabis compare to Synergy CHC?

Which has more volatility and risk, SNYR or IMCC?

Which has higher earnings and valuation, SNYR or IMCC?

Do insiders & institutionals believe in SNYR or IMCC?

Does the media prefer SNYR or IMCC?

Do analysts prefer SNYR or IMCC?

Is SNYR or IMCC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC vs. The Competition

IM Cannabis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools